| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-HP2F6 | Human | PE-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (Site-specific conjugation) |  |
||
| ILA-HF255 | Human | FITC-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) |  |
|
|
| ILA-M5253 | Mouse | Mouse IL-15 R alpha / CD215 Protein, Fc Tag |  |
|
|
| ILA-H82F4 | Human | Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| ILA-H5253 | Human | Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) |  |
|
|
Immobilized Human IL-15, Tag Free (Cat. No. IL5-H4117) at 5 μg/mL (100 μL/well) can bind Mouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) with a linear range of 0.6-10 ng/mL (QC tested).
The purity of FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) is more than 85% and the molecular weight of this protein is around 115-140 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| QL-415 | QL-415 | Phase 1 Clinical | Neoplasms | Details | |
| Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details | |
| PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) | Phase 2 Clinical | Immunitybio Inc | Pancreatic Neoplasms | Details | |
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Details |
| KD-033 | KD-033 | Takeda Pharma | Details | ||
| OXS-3550 | OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE | Oxis Biotech, University Of Minnesota | Details | ||
| SHR-1501 | SHR-1501 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Urinary Bladder Neoplasms | Details |
| Heterodimeric interleukin 15(Novartis Pharma) | NIZ-985 | Novartis Pharma Ag | Details | ||
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
| RTX-240 | RTX-240 | Rubius Therapeutics | Details | ||
| XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor | Solid tumours; Neoplasms; Multiple Myeloma | Details |
| Nanrilkefusp alfa | RLI-15; CYP-0150; SOT-101; SO-C101 | Phase 2 Clinical | Sotio | Mesothelioma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Thymus Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms | Details |
| ASKG-315 | ASKG-315; ASKG-215b; ASKG-215β | Phase 1 Clinical | Askgene Pharma | Neoplasms | Details |
| NKTR-255 | NKTR-255 | Phase 2 Clinical | Nektar Therapeutics | Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
